Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial
Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19.
Authors
- Fernando Martínez‐Valle (ORCID: https://orcid.org/0000-0003-2673-2034)
- Juan Espinosa‐Pereiro (ORCID: https://orcid.org/0000-0002-7238-8337)
- Joaquín Burgos (ORCID: https://orcid.org/0000-0001-8445-3047)
- Salvador Augustín (ORCID: https://orcid.org/0000-0002-3515-9033)
- Vicenç Falcó (ORCID: https://orcid.org/0000-0001-9626-0023)
- Alfredo Castillo (ORCID: https://orcid.org/0000-0003-0626-507X)
- Cristina Kirkegaard-Biosca
- Adrián Sánchez-Montalvá
- Júlia Sellarès-Nadal
- Juan Bañares-Sánchez
- Alba Prio-Ruatg
Institutions
- Universitat Autònoma de Barcelona (ES)
- Instituto de Salud Carlos III (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Centro de Investigación Biomédica en Red (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Infection
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1007/s15010-025-02506-y
- Citations
- 2
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Universitat Autònoma de Barcelona
- Instituto de Salud Carlos III